Jennifer R. Keeffe

This study identifies nanobodies targeting conserved SARS-CoV-2 RBD epitopes that neutralize variants and zoonotic sarbecoviruses.

This paper develops mRNA-based vaccines encoding RBD quartets and shows they match or improve antibody breadth, T-cell responses, and epitope targeting compared to protein-based vaccines.

This paper develops a gp120-specific CD4 variant (gCD4) that improves thermostability, reduces off-target class II MHC binding, and enhances HIV-1 neutralization compared to existing CD4-Ig biologics.

This paper develops a recombinant single-cycle influenza viral vector vaccine against SARS-CoV-2 and SARS-like betacoronaviruses, showing robust immune responses in mice.

This study shows a novel two-step mechanism for inducing broadly neutralizing HIV antibodies in macaques using a modified SHIV, informing vaccine design.

This study evaluates ALD-delivered mosaic-8b RBD-nanoparticles, showing improved cross-reactive antibody responses against mismatched sarbecoviruses compared to conventional immunizations.

This paper designs and tests an HIV-1 vaccine candidate that targets three bNAb epitopes, showing it elicits combined immune responses in animal models.

This paper develops mosaic RBD-nanoparticles to induce cross-reactive anti-sarbecovirus antibodies in animals, demonstrating their effectiveness against SARS-CoV-2 variants and zoonotic viruses.

The paper designs mosaic nanoparticles with SARS-like betacoronavirus RBDs to enhance cross-reactive immune responses in mice, finding that mosaic-7COM elicits stronger responses against zoonotic sarbecoviruses and Omicrons.

This study shows that sequential immunization of macaques with engineered and native-like HIV-1 Env trimers elicits antibodies that neutralize by targeting non-closed Env conformations.

The paper shows mosaic-8b nanoparticles induce broader cross-reactive antibodies than homotypic ones, even in pre-vaccinated animals, suggesting potential for improved vaccine design against emerging sarbecoviruses.

The paper detects and characterizes the SARS-CoV-2 lineage B.1.526 in New York, showing its rapid growth and potential impact on neutralization.